SPECTRAL CAPITAL Corp — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that SPECTRAL CAPITAL Corp filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $21.84M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $0 | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $0 | Jun 24, 2025 |
| FY2023 | Dec 31, 2022 | $98.3K | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $0 | Mar 27, 2023 |
| FY2021 | Dec 31, 2020 | $48 | Mar 4, 2022 |
| FY2020 | Dec 31, 2019 | $239 | Feb 18, 2021 |
| FY2019 | Dec 31, 2018 | $0 | Feb 10, 2020 |
| FY2018 | Dec 31, 2017 | $0 | Mar 13, 2019 |
| FY2012 | Dec 31, 2012 | $182.1K | Apr 16, 2013 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.88M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $0 | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $0 | Jun 24, 2025 |
| FY2023 | Dec 31, 2022 | $98.3K | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $0 | Mar 27, 2023 |
| FY2021 | Dec 31, 2020 | $48 | Mar 4, 2022 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $918.4K | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($3.27M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($215.4K) | Jun 24, 2025 |
| FY2023 | Dec 31, 2022 | ($241.0K) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($172.2K) | Mar 27, 2023 |
| FY2021 | Dec 31, 2020 | ($167.8K) | Mar 4, 2022 |
| FY2020 | Dec 31, 2019 | ($177.8K) | Feb 18, 2021 |
| FY2019 | Dec 31, 2018 | ($177.5K) | Feb 10, 2020 |
| FY2018 | Dec 31, 2017 | ($189.6K) | Mar 13, 2019 |
| FY2017 | Dec 31, 2016 | ($183.5K) | Mar 19, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($2.93M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($3.00M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($215.5K) | Jun 24, 2025 |
| FY2019 | Dec 31, 2019 | ($178.9K) | Feb 10, 2020 |
| FY2019 | Dec 31, 2018 | ($178.4K) | Feb 10, 2020 |
| FY2018 | Dec 31, 2017 | ($190.0K) | Mar 13, 2019 |
| FY2017 | Dec 31, 2016 | ($189.9K) | Mar 19, 2018 |
| FY2016 | Dec 31, 2015 | ($813.1K) | Mar 31, 2017 |
| FY2015 | Dec 31, 2014 | ($6.65M) | Mar 29, 2016 |
| FY2013 | Dec 31, 2013 | ($11.63M) | Mar 31, 2014 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $0 | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $745.0K | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $0 | Jun 24, 2025 |
| FY2015 | Dec 31, 2014 | $330.8K | Mar 29, 2016 |
| FY2014 | Dec 31, 2013 | $81.1K | Mar 19, 2015 |
| FY2012 | Dec 31, 2012 | $1.97M | Apr 16, 2013 |
| FY2011 | Dec 31, 2011 | $1.97M | Mar 30, 2012 |
| FY2011 | Dec 31, 2010 | $3.9K | Mar 30, 2012 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.08M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $1.17M | Mar 31, 2026 |
| FY2017 | Dec 31, 2017 | $38.9K | Mar 19, 2018 |
| FY2017 | Dec 31, 2016 | $39.9K | Mar 19, 2018 |
| FY2016 | Dec 31, 2015 | $76.3K | Mar 31, 2017 |
| FY2015 | Dec 31, 2014 | $225.2K | Mar 29, 2016 |
| FY2014 | Dec 31, 2013 | $232.9K | Mar 19, 2015 |
| FY2013 | Dec 31, 2012 | $272.3K | Mar 31, 2014 |
| FY2012 | Dec 31, 2011 | $1.02M | Apr 16, 2013 |
| FY2011 | Dec 31, 2010 | $74.2K | Mar 30, 2012 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($1.49M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($1.65M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($47.5K) | Jun 24, 2025 |
| FY2023 | Dec 31, 2022 | ($45.0K) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($28.5K) | Mar 27, 2023 |
| FY2021 | Dec 31, 2020 | ($23.8K) | Mar 4, 2022 |
| FY2020 | Dec 31, 2019 | ($30.0K) | Feb 18, 2021 |
| FY2019 | Dec 31, 2018 | ($28.4K) | Feb 10, 2020 |
| FY2018 | Dec 31, 2017 | ($31.6K) | Mar 13, 2019 |
| FY2017 | Dec 31, 2016 | ($38.1K) | Mar 19, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $40.4K | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $0 | Mar 31, 2026 |
| FY2013 | Dec 31, 2013 | $54.2K | Mar 31, 2014 |
| FY2012 | Dec 31, 2012 | $54.2K | Apr 16, 2013 |
| FY2011 | Dec 31, 2011 | $54.2K | Mar 30, 2012 |
| FY2011 | Dec 31, 2010 | $2.9K | Mar 30, 2012 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $114.0K | Jun 24, 2025 |
| FY2024 | Dec 31, 2023 | $240 | Jun 24, 2025 |
| FY2023 | Dec 31, 2022 | $35.7K | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $264 | Mar 27, 2023 |
| FY2021 | Dec 31, 2020 | $413 | Mar 4, 2022 |
| FY2020 | Dec 31, 2019 | $853 | Feb 18, 2021 |
| FY2019 | Dec 31, 2018 | $658 | Feb 10, 2020 |
| FY2018 | Dec 31, 2017 | $692 | Mar 13, 2019 |
| FY2017 | Dec 31, 2016 | $10.4K | Mar 19, 2018 |
| FY2016 | Dec 31, 2015 | $3.7K | Mar 31, 2017 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $106.59M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $1.03M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $332.7K | Jun 24, 2025 |
| FY2021 | Dec 31, 2021 | $1.26M | Mar 4, 2022 |
| FY2021 | Dec 31, 2020 | $1.09M | Mar 4, 2022 |
| FY2020 | Dec 31, 2019 | $922.8K | Feb 18, 2021 |
| FY2019 | Dec 31, 2018 | $743.6K | Feb 10, 2020 |
| FY2018 | Dec 31, 2017 | $565.3K | Mar 13, 2019 |
| FY2017 | Dec 31, 2016 | $727.3K | Mar 19, 2018 |
| FY2016 | Dec 31, 2015 | $539.9K | Mar 31, 2017 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $44.38M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($697.3K) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($110.6K) | Jun 24, 2025 |
| FY2023 | Dec 31, 2022 | $29.8K | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($1.04M) | Mar 27, 2023 |
| FY2021 | Dec 31, 2020 | ($868.6K) | Mar 4, 2022 |
| FY2020 | Dec 31, 2019 | ($700.8K) | Feb 18, 2021 |
| FY2019 | Dec 31, 2018 | ($523.0K) | Feb 10, 2020 |
| FY2018 | Dec 31, 2017 | ($345.5K) | Mar 13, 2019 |
| FY2017 | Dec 31, 2016 | ($498.1K) | Mar 19, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $48.70M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $0 | Mar 31, 2026 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($33.42M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($34.33M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($31.06M) | Jun 24, 2025 |
| FY2023 | Dec 31, 2022 | ($29.08M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($28.84M) | Mar 27, 2023 |
| FY2021 | Dec 31, 2020 | ($28.67M) | Mar 4, 2022 |
| FY2020 | Dec 31, 2019 | ($28.50M) | Feb 18, 2021 |
| FY2019 | Dec 31, 2018 | ($28.32M) | Feb 10, 2020 |
| FY2018 | Dec 31, 2017 | ($28.14M) | Mar 13, 2019 |
| FY2017 | Dec 31, 2016 | ($27.96M) | Mar 19, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.09M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $107.5K | Mar 31, 2026 |
| FY2025 | Dec 31, 2023 | $240 | Mar 31, 2026 |
| FY2023 | Dec 31, 2022 | $10.7K | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $264 | Mar 27, 2023 |
| FY2021 | Dec 31, 2020 | $413 | Mar 4, 2022 |
| FY2021 | Dec 31, 2019 | $853 | Mar 4, 2022 |
| FY2020 | Dec 31, 2018 | $658 | Feb 18, 2021 |
| FY2019 | Dec 31, 2017 | $692 | Feb 10, 2020 |
| FY2018 | Dec 31, 2016 | $1.2K | Mar 13, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Jun 24, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 27, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 31, 2026 |
| FY2022 | Dec 31, 2022 | 0 | Mar 27, 2023 |
| FY2022 | Dec 31, 2021 | 0 | Mar 27, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 88.25M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | 67.70M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | 42.02M | Jun 24, 2025 |
| FY2023 | Dec 31, 2022 | 42.02M | Mar 28, 2024 |
| FY2021 | Dec 31, 2021 | 117.86M | Mar 4, 2022 |
| FY2021 | Dec 31, 2020 | 117.86M | Mar 4, 2022 |
| FY2020 | Dec 31, 2019 | 117.86M | Feb 18, 2021 |
| FY2019 | Dec 31, 2018 | 117.86M | Feb 10, 2020 |
| FY2018 | Dec 31, 2017 | 117.86M | Mar 13, 2019 |
| FY2017 | Dec 31, 2016 | 117.86M | Mar 19, 2018 |